Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best up and coming stocks to buy according to Wall Street. On ...

Structure Therapeutics' (GPCR) subsidiary Gasherbrum Bio signed a patent license agreement with Genentech, granting Genentech ...

Structure Therapeutics, Inc. Sponsored ADR ( ($GPCR) ) has issued an update. On December 30, 2025, Gasherbrum Bio, a subsidiary of Structure ...

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...

Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...

Structure Therapeutics has a promising pipeline of product candidates, including GSBR-1290, a GLP-1R agonist for diabetes and obesity, and APJR and LPA1R agonists and antagonists for various ...

Scientists reveal how G protein-coupled receptors, major therapeutic drug targets, decode critical properties of their ligands. Through an international collaboration, scientists at St. Jude ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...